Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR

  1. Lookup NU author(s)
  2. Professor Ruth Plummer
  3. Dr Louise Li
  4. Rebecca Perrett
  5. Professor Alan Calvert
Author(s)Plummer ER, Vidal L, Li L, Shaw H, Perrett RH, Shahidi M, Amelsberg A, Temple G, Calvert AH, de Bono J
Publication type Article
JournalEuropean Journal of Cancer Supplements
Year2006
Volume4
Issue12
Pages173-174
ISSN (print)1359-6349
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
URLhttp://dx.doi.org/10.1016/S1359-6349(06)70578-X
DOI10.1016/S1359-6349(06)70578-X
NotesFrom conference: 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 573 Poster.
Actions    Link to this publication